Introduction: Atorvastatin exhibits wide interindividual variability in treatment response, limiting the drug efficacy in coronary artery disease patients. Aim: To study the effect of genetic variants involved in atorvastatin transport/metabolism and correlate their lipid-lowering efficacy. Materials & methods: Genotyping was performed using 5′-hydrolysis probe method (n = 412), and the study evaluated the treatment response in 86 patients. Results: Significant reduction in total cholesterol and low-density lipoprotein cholesterol (LDL-C) were observed in SLCO1B1-rs4149056, rs4363657 and ABCB1-rs1045642 genotypes. The combined genotypes of ABCB1 and SLCO1B1 showed a strong synergistic effect in reducing the total cholesterol and LDL-C. Diabetes and smoking were observed to influence the LDL-C reduction. Conclusion: The genetic variants of SLCO1B1 and ABCB1 predict the lipid-lowering efficacy of atorvastatin, and this may be useful in genotype-guided statin therapy for coronary artery disease patients.

Status of diabetes of an individual is majorly evaluated by the frequent monitoring of glucose estimation. Use of serum samples and inappropriate plasma for estimating glucose is an existing practise in Indian standard of laboratories. There is a strong evidence for occurrence of in vitro glycolysis on the above mentioned specimens. The aim is to study the pre-analytical variations on the glucose estimation of using sodium fluoride-disodium EDTA (NaF-Na2EDTA) plasma (glycolysis inhibiting anticoagulant) and determine the fact behind the activity of glycolysis inhibition on the same. Healthy volunteers 20-35 years of both genders consisting of 40 members were selected for the study, and after getting the informed consent form, random blood samples were collected to study the errors of pre-analytical i.e., mixing of NaF-Na2EDTA tube by phlebotomist (no of inversion). Difference in duration from blood collection to centrifugation and a variable in time were taken from centrifugation to analyzing the plasma sample. Comparative studies on EDTA plasma and serum sample were also carried out. The usage of the evacuated blood collection system on NaF-Na2EDTA was shown to have the complete glycolysis inhibitor among all pre-analytical errors, whereas other tubes shown considerable increase in glycolysis. Recently the use of glycolysis inhibitor tubes are come into practise only in accredited or certified laboratories. Hence the authentication of glycolysis inhibition study is mandatory for the pre-analytical variations on the same.

Objective: The purpose of this work is to evaluate the antimicrobial, antibacterial, and hypoglycemic effects of methanolic and ethanolic extracts of Embelia ribes leaves using in vitro studies.Methods: Antibacterial activities of the methanolic and ethanolic extract of E. ribes leaves against Escherichia coli, Staphylococcus aureus, Enterococci, and Klebsiella pneumoniae at different concentrations ranging from 10, 25, 50, and 75 μg/mL and their antibacterial activities were compared to those of the reference controls such as ciprofloxacin and clindamycin. Furthermore, the effect of leaf extracts on α-amylase and α-glucosidase enzymes was assayed.Results: The methanolic and ethanolic extract of E. ribes leaves effectively inhibited the activity of α-amylase and α-glucosidase in a dose-dependent manner. The effect of the methanolic extract was more prominent than that of ethanolic extract. At the same time, both the extracts showed markable inhibition of bacterial growth at a concentration of 75 μg/mL compared to the other three doses (10, 25, and 50 μg/ml) and also commercially available antibiotic drugs ciprofloxacin and clindamycin that were used as positive control drugs. The antibacterial activity of methanolic extract is significantly higher than that of ethanolic extract.Conclusion: The preliminary results of this study have put forward E. ribes into promising herb with respect to its therapeutic potential although further studies are needed to evaluate its mechanism of action.

Objective: The purpose of this work is to evaluate the antimicrobial, antibacterial, and hypoglycemic effects of methanolic and ethanolic extracts of Embelia ribes leaves using in vitro studies.Methods: Antibacterial activities of the methanolic and ethanolic extract of E. ribes leaves against Escherichia coli, Staphylococcus aureus, Enterococci, and Klebsiella pneumoniae at different concentrations ranging from 10, 25, 50, and 75 μg/mL and their antibacterial activities were compared to those of the reference controls such as ciprofloxacin and clindamycin. Furthermore, the effect of leaf extracts on α-amylase and α-glucosidase enzymes was assayed.Results: The methanolic and ethanolic extract of E. ribes leaves effectively inhibited the activity of α-amylase and α-glucosidase in a dose-dependent manner. The effect of the methanolic extract was more prominent than that of ethanolic extract. At the same time, both the extracts showed markable inhibition of bacterial growth at a concentration of 75 μg/mL compared to the other three doses (10, 25, and 50 μg/ml) and also commercially available antibiotic drugs ciprofloxacin and clindamycin that were used as positive control drugs. The antibacterial activity of methanolic extract is significantly higher than that of ethanolic extract.Conclusion: The preliminary results of this study have put forward E. ribes into promising herb with respect to its therapeutic potential although further studies are needed to evaluate its mechanism of action.

Objective: The purpose of this work is to evaluate the antimicrobial, antibacterial, and hypoglycemic effects of methanolic and ethanolic extracts of Embelia ribes leaves using in vitro studies.Methods: Antibacterial activities of the methanolic and ethanolic extract of E. ribes leaves against Escherichia coli, Staphylococcus aureus, Enterococci, and Klebsiella pneumoniae at different concentrations ranging from 10, 25, 50, and 75 μg/mL and their antibacterial activities were compared to those of the reference controls such as ciprofloxacin and clindamycin. Furthermore, the effect of leaf extracts on α-amylase and α-glucosidase enzymes was assayed.Results: The methanolic and ethanolic extract of E. ribes leaves effectively inhibited the activity of α-amylase and α-glucosidase in a dose-dependent manner. The effect of the methanolic extract was more prominent than that of ethanolic extract. At the same time, both the extracts showed markable inhibition of bacterial growth at a concentration of 75 μg/mL compared to the other three doses (10, 25, and 50 μg/ml) and also commercially available antibiotic drugs ciprofloxacin and clindamycin that were used as positive control drugs. The antibacterial activity of methanolic extract is significantly higher than that of ethanolic extract.Conclusion: The preliminary results of this study have put forward E. ribes into promising herb with respect to its therapeutic potential although further studies are needed to evaluate its mechanism of action.